Basis: Current FMP quote-based enterprise value / four-quarter operating income. Source: stored company filings and market data; unavailable inputs remain N/A.
The EV/EBIT ratio is N/A as of 2026-10-06T16:57:10.002Z.
Calculation as of: 2026-10-06T16:57:10.002Z.
Quote observation: 2026-10-06T16:55:13.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: 84f755396c9cc6b6c9535f897ba0f48fef5a33e79b5fb4c136097311f2feddf3
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation. Historical series through 2024-05-08.
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
EV/EBIT RATIO
N/A
EV/EBIT RATIO AVG TTM
N/A
EV/EBIT RATIO AVG 3Y
N/A
EV/EBIT RATIO AVG 5Y
N/A
EV/EBIT RATIO AVG 10Y
N/A
EV/EBIT RATIO AVG 15Y
N/A
EV/EBIT RATIO AVG 20Y
N/A
CURRENT VS TTM AVG
N/A
CURRENT VS 3Y AVG
N/A
CURRENT VS 5Y AVG
N/A
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
Market Cap
$1.10M
EV/EBIT Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$1.03M
EV/EBIT Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
| NAME | MARKET CAP | EV/EBIT RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| IM Cannabis Corp. (IMCC) | $1.15M | N/A | N/A | N/A | N/A |
| Propanc Biopharma, Inc. (PPCB)vs › | $1.14M | N/A | N/A | N/A | N/A |
| Cellyan Biotechnology Co., Ltd (HKPD)vs › | $1.10M | N/A | N/A | N/A | N/A |
| Jupiter Neurosciences, Inc. (JUNS)vs › | $1.25M | N/A | N/A | N/A | N/A |
| Clearmind Medicine Inc. (CMND)vs › | $1.07M | N/A | N/A | N/A | N/A |
| Aspire Biopharma Holdings, Inc. (ASBP)vs › | $1.03M | N/A | N/A | N/A | N/A |
| NewcelX Ltd. (NCEL)vs › | $1.32M | N/A | N/A | N/A | N/A |
| Genprex, Inc. (GNPX)vs › | $1.34M | N/A | N/A | N/A | N/A |
| Artelo Biosciences, Inc. (ARTL)vs › | $1.38M | N/A | N/A | N/A | N/A |
| GlucoTrack, Inc. (GCTK)vs › | $881948.00 | N/A | 1487.85x | 7742.21x | 7742.21x |
EV/EBIT = Enterprise Value / EBIT (TTM)
Enterprise value to EBIT compares total company value to operating earnings, accounting for depreciation unlike EV/EBITDA.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | EV/EBIT RATIO |
|---|---|
| 2024-05-08 | 10.69x |
| 2024-05-07 | 11.21x |
| 2024-05-06 | 11.24x |
| 2024-05-03 | 11.89x |
| 2024-05-02 | 12.04x |
| 2024-05-01 | 13.56x |
| 2024-04-30 | 11.66x |
| 2024-04-29 | 9.38x |
| 2024-04-26 | 9.34x |
| 2024-04-25 | 9.43x |
| 2024-04-24 | 9.14x |
| 2024-04-23 | 9.46x |
| 2024-04-22 | 9.67x |
| 2024-04-19 | 9.74x |
| 2024-04-18 | 9.61x |
| 2024-04-17 | 9.41x |
| 2024-04-16 | 9.05x |
| 2024-04-15 | 9.53x |
| 2024-04-12 | 9.90x |
| 2024-04-11 | 10.65x |
| 2024-04-10 | 10.74x |
| 2024-04-09 | 11.04x |
| 2024-04-08 | 12.27x |
| 2024-04-05 | 11.66x |
| 2024-04-04 | 13.34x |
| 2024-04-03 | 12.52x |
| 2024-04-02 | 10.88x |
| 2024-04-01 | 10.76x |
